306 related articles for article (PubMed ID: 35137398)
1. Effector immune cells in chronic lung allograft dysfunction: A systematic review.
Bos S; Filby AJ; Vos R; Fisher AJ
Immunology; 2022 May; 166(1):17-37. PubMed ID: 35137398
[TBL] [Abstract][Full Text] [Related]
2. BAL Fluid Eosinophilia Associates With Chronic Lung Allograft Dysfunction Risk: A Multicenter Study.
Todd JL; Weber JM; Kelly FL; Neely ML; Mulder H; Frankel CW; Nagler A; McCrae C; Newbold P; Kreindler J; Palmer SM
Chest; 2023 Sep; 164(3):670-681. PubMed ID: 37003354
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy of chronic lung allograft dysfunction post lung transplantation.
Evans RA; Walter KS; Lobo LJ; Coakley R; Doligalski CT
Clin Transplant; 2022 Aug; 36(8):e14770. PubMed ID: 35801376
[TBL] [Abstract][Full Text] [Related]
4. Fibroproliferation in chronic lung allograft dysfunction: Association of mesenchymal cells in bronchoalveolar lavage with phenotypes and survival.
Combs MP; Xia M; Wheeler DS; Belloli EA; Walker NM; Braeuer RR; Lyu DM; Murray S; Lama VN
J Heart Lung Transplant; 2020 Aug; 39(8):815-823. PubMed ID: 32360292
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.
Leuschner G; Lauseker M; Howanietz AS; Milger K; Veit T; Munker D; Schneider C; Weig T; Michel S; Barton J; Meiser B; Dinkel J; Neurohr C; Behr J; Kneidinger N
J Heart Lung Transplant; 2020 Nov; 39(11):1270-1278. PubMed ID: 32917480
[TBL] [Abstract][Full Text] [Related]
6. Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung Transplantation.
Shino MY; Weigt SS; Li N; Derhovanessian A; Sayah DM; Huynh RH; Saggar R; Gregson AL; Ardehali A; Ross DJ; Lynch JP; Elashoff RM; Belperio JA
Am J Transplant; 2017 May; 17(5):1294-1303. PubMed ID: 27676455
[TBL] [Abstract][Full Text] [Related]
7. Chronic Lung Allograft Dysfunction: A Systematic Review of Mechanisms.
Royer PJ; Olivera-Botello G; Koutsokera A; Aubert JD; Bernasconi E; Tissot A; Pison C; Nicod L; Boissel JP; Magnan A;
Transplantation; 2016 Sep; 100(9):1803-14. PubMed ID: 27257997
[TBL] [Abstract][Full Text] [Related]
8. Plasma CXCL9 and CXCL10 at allograft injury predict chronic lung allograft dysfunction.
Shino MY; Todd JL; Neely ML; Kirchner J; Frankel CW; Snyder LD; Pavlisko EN; Fishbein GA; Schaenman JM; Mason K; Kesler K; Martinu T; Singer LG; Tsuang W; Budev M; Shah PD; Reynolds JM; Williams N; Robien MA; Palmer SM; Weigt SS; Belperio JA
Am J Transplant; 2022 Sep; 22(9):2169-2179. PubMed ID: 35634722
[TBL] [Abstract][Full Text] [Related]
9. Connective Tissue Growth Factor Is Overexpressed in Explant Lung Tissue and Broncho-Alveolar Lavage in Transplant-Related Pulmonary Fibrosis.
Vanstapel A; Goldschmeding R; Broekhuizen R; Nguyen T; Sacreas A; Kaes J; Heigl T; Verleden SE; De Zutter A; Verleden G; Weynand B; Verbeken E; Ceulemans LJ; Van Raemdonck DE; Neyrinck AP; Schoemans HM; Vanaudenaerde BM; Vos R
Front Immunol; 2021; 12():661761. PubMed ID: 34122421
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers for Chronic Lung Allograft Dysfunction: Ready for Prime Time?
Verleden SE; Hendriks JMH; Lauwers P; Yogeswaran SK; Verplancke V; Kwakkel-Van-Erp JM
Transplantation; 2023 Feb; 107(2):341-350. PubMed ID: 35980878
[TBL] [Abstract][Full Text] [Related]
11. Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction.
Iasella CJ; Hoji A; Popescu I; Wei J; Snyder ME; Zhang Y; Xu W; Iouchmanov V; Koshy R; Brown M; Fung M; Langelier C; Lendermon EA; Dugger D; Shah R; Lee J; Johnson B; Golden J; Leard LE; Ellen Kleinhenz M; Kilaru S; Hays SR; Singer JP; Sanchez PG; Morrell MR; Pilewski JM; Greenland JR; Chen K; McDyer JF
Am J Transplant; 2021 Jun; 21(6):2145-2160. PubMed ID: 33078555
[TBL] [Abstract][Full Text] [Related]
12. Inflammation on bronchoalveolar lavage cytology is associated with decreased chronic lung allograft dysfunction-free survival.
Greenland NY; Deiter F; Calabrese DR; Hays SR; Kukreja J; Leard LE; Kolaitis NA; Golden JA; Singer JP; Greenland JR
Clin Transplant; 2022 Jun; 36(6):e14639. PubMed ID: 35246990
[TBL] [Abstract][Full Text] [Related]
13. Epithelial cell death markers in bronchoalveolar lavage correlate with chronic lung allograft dysfunction subtypes and survival in lung transplant recipients-a single-center retrospective cohort study.
Levy L; Tigert A; Huszti E; Saito T; Mitsakakis N; Moshkelgosha S; Joe B; Boonstra KM; Tikkanen JM; Keshavjee S; Juvet SC; Martinu T
Transpl Int; 2019 Sep; 32(9):965-973. PubMed ID: 31002407
[TBL] [Abstract][Full Text] [Related]
14. Early posttransplant reductions in club cell secretory protein associate with future risk for chronic allograft dysfunction in lung recipients: results from a multicenter study.
Todd JL; Weber JM; Kelly FL; Neely ML; Nagler A; Carmack D; Frankel CW; Brass DM; Belperio JA; Budev MM; Hartwig MG; Martinu T; Reynolds JM; Shah PD; Singer LG; Snyder LD; Weigt SS; Palmer SM
J Heart Lung Transplant; 2023 Jun; 42(6):741-749. PubMed ID: 36941179
[TBL] [Abstract][Full Text] [Related]
15. Gene Expression Profiling of Bronchoalveolar Lavage Cells During Aspergillus Colonization of the Lung Allograft.
Weigt SS; Wang X; Palchevskiy V; Patel N; Derhovanessian A; Shino MY; Sayah DM; Lynch JP; Saggar R; Ross DJ; Kubak BM; Ardehali A; Palmer S; Husain S; Belperio JA
Transplantation; 2018 Jun; 102(6):986-993. PubMed ID: 29256975
[TBL] [Abstract][Full Text] [Related]
16. Emerging biomarkers in chronic lung allograft dysfunction.
Shtraichman O; Diamond JM
Expert Rev Mol Diagn; 2020 May; 20(5):467-475. PubMed ID: 32133875
[No Abstract] [Full Text] [Related]
17. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
18. Validation of a post-transplant chronic lung allograft dysfunction classification system.
Van Herck A; Verleden SE; Sacreas A; Heigl T; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck D; Verleden GM; Vos R
J Heart Lung Transplant; 2019 Feb; 38(2):166-173. PubMed ID: 30391199
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunity in phenotypes of chronic lung allograft dysfunction: A broncho-alveolar lavage fluid analysis.
Vandermeulen E; Verleden SE; Bellon H; Ruttens D; Lammertyn E; Claes S; Vandooren J; Ugarte-Berzal E; Schols D; Emonds MP; Van Raemdonck DE; Opdenakker G; Verleden GM; Vos R; Vanaudenaerde BM
Transpl Immunol; 2016 Sep; 38():27-32. PubMed ID: 27561239
[TBL] [Abstract][Full Text] [Related]
20. BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients.
Berastegui C; Gómez-Ollés S; Sánchez-Vidaurre S; Culebras M; Monforte V; López-Meseguer M; Bravo C; Ramon MA; Romero L; Sole J; Cruz MJ; Román A
Clin Transplant; 2017 Mar; 31(3):. PubMed ID: 28008659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
